Nasdaq:REVB
REVELATION BIOSCIENCES, INC.
A clinical-stage biotech firm targeting cancer and immune diseases with a focus on advancing proprietary therapeutic platforms.
Key Metrics
Investment Thesis
Bull Case
Investors may be attracted to REVB for exposure to a differentiated technology platform with high potential upside if clinical trials succeed and regulatory approval is obtained. The company's current cash position provides sufficient runway to continue advancing its pipeline without immediate need for dilutive fundraising, assuming no major setbacks occur. Successful commercialization of its oncology or immunology therapies could generate substantial future revenue streams and market share.
Bear Case
The stock carries extreme risk due to zero revenue and a persistent annualized net loss that has widened significantly in recent years. Investors face the prospect of further dilution through equity issuances as the company burns through its $10.7M cash reserves to fund operations. Without proven clinical efficacy or strategic partnerships, the asset value remains speculative and highly sensitive to regulatory outcomes.
About REVELATION BIOSCIENCES, INC.
REVELATION BIOSCIENCES, INC. (REVB) is a clinical-stage biotechnology company focused on developing next-generation therapies for oncology and immunology. The company leverages its proprietary platform to identify novel drug targets and advance candidates through preclinical and clinical development phases. Operations are currently centered on research and development activities rather than commercial product sales.
Analysis
Management Discussion
Financial performance for 2024 shows a net loss of $-8.9M, driven by substantial research and development expenditures totaling $4.1M alongside general administrative costs of $5.0M. Despite maintaining a cash balance of $10.7M, the company generated negative operating cash flow of $-8.3M, highlighting the capital-intensive nature of its clinical-stage pipeline. The significant increase in retained earnings deficit to $-49.4M underscores the cumulative burn rate required to advance its therapeutic candidates toward market entry.
Industry Overview
The biotechnology sector is characterized by high failure rates in drug development and a long timeline from discovery to commercialization. Companies often operate at a loss for years while investing heavily in R&D to bring novel therapies to market. Regulatory hurdles from agencies like the FDA are stringent, requiring substantial investment before products can be sold.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| Operating Expenses | $10.9M | $8.7M | $8.0M | $9.1M |
| Operating Income | $-10.9M | $-8.7M | $-8.0M | $-9.1M |
| R&D | $5.4M | $4.1M | $3.5M | $4.1M |
| G&A | $5.5M | $4.5M | $4.4M | $5.0M |
| Stock-Based Comp | $301.1K | $155.7K | $168.8K | $595.4K |
| Depreciation | $25.0K | $25.0K | $27.9K | $27.1K |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Pre-Tax Income | $-10.9M | $-8.7M | $-8.0M | $-9.1M |
| Income Tax | $0 | $0 | $0 | $0 |
| Continuing Ops | $-10.9M | $-8.7M | $-8.0M | $-9.1M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-10.8M | $-120.3K | $-15.0M | $-8.9M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-10.8M | $-120.3K | $-15.0M | $-8.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $5.4M | $12.1M | $6.6M | $10.8M |
| Cash & Equivalents | $5.3M | $12.0M | $6.5M | $10.7M |
| Prepaid Expenses | $73.1K | $84.7K | $66.7K | $111.3K |
| Other Current Assets | $87.2K | $71.1K | $0 | $0 |
| Long-Term Assets | $90.1K | $65.1K | $56.3K | $771.3K |
| PP&E (Net) | $90.1K | $65.1K | $56.3K | $18.1K |
| Operating Leases | — | — | — | $722.3K |
| Other LT Assets | $0 | $0 | $0 | $30.9K |
| Total Assets | $5.5M | $12.2M | $6.6M | $11.6M |
| Current Liabilities | $4.5M | $5.6M | $1.9M | $2.0M |
| Accounts Payable | $554.2K | $1.4M | $783.6K | $577.5K |
| Current Leases | — | — | — | $23.0K |
| Other Current Liab | $2.9M | $3.1M | $2.2K | $0 |
| Long-Term Liabilities | $0 | $0 | $0 | $723.8K |
| LT Operating Leases | — | — | — | $723.8K |
| Other LT Liab | — | — | — | $0 |
| Total Liabilities | $4.5M | $5.6M | $1.9M | $2.7M |
| Shareholders' Equity | $1.1M | $6.6M | $4.7M | $8.9M |
| Paid-In Capital | $26.4M | $32.1M | $45.2M | $58.3M |
| Retained Earnings | $-25.3M | $-25.5M | $-40.5M | $-49.4M |
| Total L&E | $5.5M | $12.2M | $6.6M | $11.6M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-10.8M | $-120.3K | $-15.0M | $-8.9M |
| Non-Cash Adjustments | $1.5M | $-8.1M | $247.4K | $499.0K |
| Working Capital Changes | $-1.8M | $923.2K | $-3.5M | $145.0K |
| Cash from Operations | $-11.2M | $-7.3M | $-18.3M | $-8.3M |
| Capital Expenditures | — | — | $19.2K | — |
| Cash from Investing | $0 | $0 | $-19.2K | $0 |
| Cash from Financing | $15.2M | $14.0M | $12.8M | $12.5M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $4.0M | $6.7M | $-5.5M | $4.2M |
| Beginning Cash | $1.3M | $5.3M | $12.0M | $6.5M |
| Ending Cash | $5.3M | $12.0M | $6.5M | $10.7M |
Frequently Asked Questions
How does REVELATION BIOSCIENCES, INC. make money?
The company's operations are primarily driven by its R&D segment, which encompasses target identification, drug discovery, preclinical development, and early-stage clinical trials. Revenue generation is currently non-existent as the company operates in a cash-burn model typical of late-stage biotech firms awaiting regulatory approval for commercialization.
What are the main risks for REVB?
Significant negative cash flow from operations indicates a heavy reliance on external financing, creating refinancing risk if capital markets tighten. The absence of current revenue exposes the company to high volatility and potential dilution through equity offerings to fund ongoing R&D expenses. Failure to advance key clinical candidates or secure regulatory approval could result in total loss of invested capital and shareholder value.
What is REVB's competitive advantage?
The company possesses a proprietary platform technology that may accelerate the discovery of novel drug targets compared to traditional methods. A highly specialized and experienced scientific management team with deep expertise in oncology and immunology enhances execution capability. Strategic partnerships or licensing agreements could provide alternative revenue streams once clinical milestones are achieved.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.